Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients

Purpose The aim of this study was to compare the difference in disease-free survival (DFS) and overall survival (OS) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in our Hispanic population with breast cancer (BC). Methods We retrospectively analyzed a database of 4533...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research and treatment 2019-07, Vol.176 (1), p.243-249
Hauptverfasser: Flores-Díaz, Diana, Arce, Claudia, Flores-Luna, Lourdes, Reynoso-Noveron, Nancy, Lara-Medina, Fernando, Matus, Juan Antonio, Bargallo-Rocha, Enrique, Pérez, Víctor, Villarreal-Garza, Cynthia, Cabrera-Galeana, Paula, Mohar, Alejandro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose The aim of this study was to compare the difference in disease-free survival (DFS) and overall survival (OS) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in our Hispanic population with breast cancer (BC). Methods We retrospectively analyzed a database of 4533 non-metastatic BC patients treated for BC at the National Cancer Institute in Mexico (INCan) between 2006 and 2016. We compared clinical characteristics, treatment and survival between women with invasive ductal and invasive lobular BC. We evaluated differences between survival curves with the log-rank test and used Cox’s proportional hazards model for the multivariate analysis. Results Median follow-up time was 42.13 months (IQ 25 25.2–IQ 75 72.06). The median age was 50.9 years (IQ 25 43.5–IQ 75 59.8). DFS at 5 years was 80.8% for IDC versus 76.2% for ILC. 5 years OS was 88.7% for IDC versus 84.3% for ILC. Multivariate analysis showed that factors that negatively affected the 5-year DFS include: clinical stage III [hazard ratio (HR) 4.2, 95% CI 3.36–5.35; p  
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-019-05234-8